Hypertrophic Cardiomyopathy

  • Elijah R. Behr
  • William J. McKenna

Opinion statement

When an individual is diagnosed with hypertrophic cardiomyopathy (HCM), all relatives potentially affected by Mendelian autosomal-dominant inheritance should be evaluated with an electrocardiogram (ECG) and echocardiogram. Genetic testing should be considered in high-risk mutations where there are diagnostic uncertainties. Symptom relief depends on β-blockers as first-line therapy. If the disease is nonobstructive, then calcium channel blockers can be added or used alone. If there is a significant left ventricular outflow tract (LVOT) gradient then disopyramide can be used, ideally in combination with a β-blocker. Verapamil should be used with care due to potential exacerbation of the LVOT gradient. Nonmedical therapy for obstructive disease consists of surgical myectomy, alcohol septal ablation, or dual-chamber pacing. Surgery is the gold standard, although in experienced hands and directed appropriately, septal ablation achieves good results. Pacing is generally less effective. The development of atrial fibrillation (AF) or left atrial enlargement carries a significant risk of thromboembolism. All patients should be closely observed for AF and thromboembolic risk, and the threshold for initiation of anticoagulation should be low in patients with sustained palpitations, atrial enlargement, and nonsustained supraventricular arrhythmia on Holter. All patients with HCM should be assessed for their risk of sudden death regardless of severity of symptoms or morphology. The factors predictive of risk are 1) previous cardiac arrest; 2) unexplained syncope; 3) family history of premature sudden death; 4) abnormal blood pressure response to exercise; 5) nonsustained ventricular tachycardia; and 6) severe left ventricular hypertrophy ≥ 30 mm.


Amiodarone Sudden Death Implantable Cardioverter Defibrillator Hypertrophic Cardiomyopathy Main Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Bulkley BH, Weisfeldt ML, Hutchins GM: Asymmetric septal hypertrophy and myocardial fiber disarray. Features of normal, developing, and malformed hearts. Circulation 1977, 56:292–298.PubMedGoogle Scholar
  2. 2.
    Davies MJ: The current status of myocardial disarray in hypertrophic cardiomyopathy [editorial]. Br Heart J 1984, 51:361–363.PubMedGoogle Scholar
  3. 3.
    Maron BJ, Roberts WC: Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circulation 1979, 59:689–706.PubMedGoogle Scholar
  4. 4.
    Richardson P, McKenna W, Bristow M, et al.: Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies [news]. Circulation 1996, 93:841–842.PubMedGoogle Scholar
  5. 5.
    Codd MB, Sugrue DD, Gersh BJ, Melton LJ: Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. Circulation 1989, 80:564–572.PubMedGoogle Scholar
  6. 6.
    Maron BJ, Gardin JM, Flack JM, et al.: Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995, 92:785–789.PubMedGoogle Scholar
  7. 7.
    McKenna WJ, Behr ER: Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 2002, 87:169–176.PubMedCrossRefGoogle Scholar
  8. 8.
    Elliott PM, Poloniecki J, Dickie S, et al.: Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000, 36:2212–2218. This paper provides a prospective analysis of outcomes in a large cohort of HCM patients. It indicates factors associated with increased risk of sudden death and provides a statistical basis for determining individual risk and the need for treatment.PubMedCrossRefGoogle Scholar
  9. 9.
    Cecchi F, Olivotto I, Montereggi A, et al.: Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995, 26:1529–1536.PubMedCrossRefGoogle Scholar
  10. 10.
    Maron BJ, Casey SA, Poliac LC, et al.: Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999, 281:650–655. [Published erratum appears in JAMA 1999, 281:2288.]PubMedCrossRefGoogle Scholar
  11. 11.
    Maron BJ, Shen WK, Link MS, et al.: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365–373. This registry data deals with the largest cohort of HCM patients with ICDs and provides justification of device therapy as well as cautionary messages on the risks of interventions.PubMedCrossRefGoogle Scholar
  12. 12.
    Stafford WJ, Trohman RG, Bilsker M, et al.: Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986, 7:701–704.PubMedCrossRefGoogle Scholar
  13. 13.
    Olivotto I, Cecchi F, Casey SA, et al.: Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001, 104:2517–2524.PubMedGoogle Scholar
  14. 14.
    Spirito P, Maron BJ, Bonow RO, Epstein SE: Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987, 60:123–129.PubMedCrossRefGoogle Scholar
  15. 15.
    Knight CJ: Five years of percutaneous transluminal septal myocardial ablation. Heart 2000, 83:255–256.PubMedCrossRefGoogle Scholar
  16. 16.
    SeggewissH, Faber L, Gleichmann U: Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999, 47:94–100. This study reports on the largest series of patients undergoing septal alcohol ablation, and it supports the safety and efficacy of the procedure.PubMedCrossRefGoogle Scholar
  17. 17.
    Nishimura RA, Trusty JM, Hayes DL, et al.: Dualchamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 1997, 29:435–441.PubMedCrossRefGoogle Scholar
  18. 18.
    McCully RB, Nishimura RA, Tajik AJ, et al.: Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996, 94:467–471.PubMedGoogle Scholar
  19. 19.
    McKenna WJ, Harris L, Rowland E, et al.: Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Am J Cardiol 1984, 54:802–810.PubMedCrossRefGoogle Scholar
  20. 20.
    Fananapazir L, Tracy CM, Leon MB, et al.: Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation 1989, 80:1259–1268.PubMedGoogle Scholar
  21. 21.
    McKenna WJ, Oakley CM, Krikler DM, Goodwin JF: Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985, 53:412–416.PubMedGoogle Scholar
  22. 22.
    Nicod P, Polikar R, Peterson KL: Hypertrophic cardiomyopathy and sudden death. N Engl J Med 1988, 318:1255–1257.PubMedCrossRefGoogle Scholar
  23. 23.
    Maron BJ, Roberts WC, McAllister HA, et al.: Sudden death in young athletes. Circulation 1980, 62:218–229.PubMedGoogle Scholar
  24. 24.
    Maron BJ, Bonow RO, Cannon RO, et al.: Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 1987, 316:844–852.PubMedCrossRefGoogle Scholar
  25. 25.
    McKenna W, Elliott PM: Hypertrophic cardiomyopathy. In Comprehensive Cardiovascular Medicine. Edited by Topol EJ. Philadelphia, PA: Lipincott-Raven;1998:775–798.Google Scholar
  26. 26.
    Pollick C, Kimball B, Henderson M, Wigle ED: Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol 1988, 62:1248–1251.PubMedCrossRefGoogle Scholar
  27. 27.
    Pollick C: Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration. Am J Cardiol 1988, 62:1252–1255.PubMedCrossRefGoogle Scholar
  28. 28.
    Pollick C: Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982, 307:997–999.PubMedCrossRefGoogle Scholar
  29. 29.
    Doval HC, Nul DR, Grancelli HO, et al.: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994, 344:493–498.PubMedCrossRefGoogle Scholar
  30. 30.
    Maron BJ, Nishimura RA, McKenna WJ, et al.: Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, crossover study (M-PATHY). Circulation 1999, 99:2927–2933.PubMedGoogle Scholar
  31. 31.
    Elliott PM, Sharma S, Varnava A, et al.: Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999, 33:1596–1601.PubMedCrossRefGoogle Scholar
  32. 32.
    Wilson WR, Greer GE, Grubb BP: Implantable cardioverter-defibrillators in children: a single-institutional experience. Ann Thorac Surg 1998, 65:775–778.PubMedCrossRefGoogle Scholar
  33. 33.
    Robbins RC, Stinson EB: Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 1996, 111:586–594.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Elijah R. Behr
    • 1
  • William J. McKenna
    • 1
  1. 1.Cardiological SciencesSt. George’s Hospital Medical SchoolLondonUK

Personalised recommendations